Tissue-resident NK cells support survival in pancreatic cancer through promotion of cDC1-CD8T activity
S. Go, C. Demetriou, G. Valenzano, S. Hughes, S. Lanfredini, H. Ferry, E. Arbe-Barnes, S. Sivakumar, R. Bashford-Rogers, M. R. Middleton, S. Mukherjee, J. Morton, K. Jones, E. O'Neill
Abstract
The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T cell activity) have had limited success. Here we demonstrate how inducing localized physical damage using ionizing radiation (IR) unmasks the benefit of immunotherapy by increasing tissue-resident NK (trNK) cells that support CD8 T activity. Our data confirms that targeting mouse orthotopic PDAC tumors with IR together with CCR5 inhibition and PD1 blockade reduces E-cadherin positive tumor cells by recruiting a hypoactive NKG2D-ve NK population, phenotypically reminiscent of trNK cells, that supports CD8 T cell involvement. We show an equivalent population in human PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5i/PD1 and IR-induced damage as a novel therapeutic approach.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Strength in Unity: a Dual Strategy to Restore NK Cell Cytotoxicity against Pancreatic Ductal Adenocarcinoma
Camille Rolin, Aubin Pitiot, … Carole Seguin‐Devaux·bioRxiv·Feb 11, 2026
- Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition
Stacey N. Lee, Riley J. Arseneau, … Jeanette E. Boudreau·Journal for ImmunoTherapy of CancerPeer-reviewed·Feb 1, 2026
- Interleukin 6 drives durable T cell-mediated immunity to pancreatic cancer
Paige C. Arneson‐Wissink, Alexandra Q. Bartlett, … Aaron J. Grossberg·Cellular and Molecular Gastroenterology and HepatologyPeer-reviewed·Jan 1, 2026
- TNFR2 blockade promotes anti-tumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion
A. Debesset, C. Pilon, … J. L. Cohen·bioRxiv·Jan 22, 2024
- Improving SBRT by re-wiring immunosuppressive neutrophils in murine pancreatic ductal adenocarcinoma
Joseph D. Murphy, Gary Hannon, … Scott A. Gerber·International Journal of Radiation Oncology*Biology*PhysicsPeer-reviewed·Jul 2, 2025
- Functional T cells trapped behind a stromal wall: a Brake-with-Wall phenotype redefines pancreatic adenocarcinoma immunotherapy resistance
Jeongsoon Yong·bioRxiv·May 14, 2026